Abstract：
OBJECTIVE: Recent clinical trials have shown promising results with drugs targeting the hepatocyte growth factor receptor (c-Met) for advanced non-small cell lung cancers overexpressing c-Met. We assessed reflex testing of c-Met immunohistochemistry (IHC) at diagnosis for NSCLC in the real-world.
METHODS: We retrospectively collected clinical, pathological and molecular data of cases diagnosed with NSCLC in our institution from January 2021 to June 2023. We performed c-Met IHC (SP44 clone) and scored the expression using a H-score and a three-tier classification.
RESULTS: 391 cases with interpretable c-Met IHC staining were included. The median age at diagnosis was 70 years (range 25-89 years) including 234 males (male/female ratio 1:5). 58% of the samples came from surgical resections, 35% from biopsies and 8% from cytological procedures. 52% of cases were classified as c-Met-positive (H-score≥150) and 19% were classified as c-Methigh (≥50%, 3+). 43% of the c-Metneg presented with lymph node and/or visceral metastases at diagnosis vs 55% for c-Methigh (p=0.042). 23% of the adenocarcinomas showed c-Methigh expression vs 3% for squamous cell carcinomas (p=0.004). 27% of the c-Metneg cases had a high PD-L1 expression vs 58% of c-Methigh cases (p<0.001). MET ex14 skipping was present in 8% of the c-Methigh cases.
CONCLUSIONS: Systematic c-Met testing in daily routine for NSCLC patients is feasible, highlighting a potential correlation with clinicopathological and molecular features.
METHODS: We retrospectively collected clinical, pathological and molecular data of cases diagnosed with NSCLC in our institution from January 2021 to June 2023. We performed c-Met IHC (SP44 clone) and scored the expression using a H-score and a three-tier classification.
RESULTS: 391 cases with interpretable c-Met IHC staining were included. The median age at diagnosis was 70 years (range 25-89 years) including 234 males (male/female ratio 1:5). 58% of the samples came from surgical resections, 35% from biopsies and 8% from cytological procedures. 52% of cases were classified as c-Met-positive (H-score≥150) and 19% were classified as c-Methigh (≥50%, 3+). 43% of the c-Metneg presented with lymph node and/or visceral metastases at diagnosis vs 55% for c-Methigh (p=0.042). 23% of the adenocarcinomas showed c-Methigh expression vs 3% for squamous cell carcinomas (p=0.004). 27% of the c-Metneg cases had a high PD-L1 expression vs 58% of c-Methigh cases (p<0.001). MET ex14 skipping was present in 8% of the c-Methigh cases.
CONCLUSIONS: Systematic c-Met testing in daily routine for NSCLC patients is feasible, highlighting a potential correlation with clinicopathological and molecular features.
摘要：
目的：最近的临床试验显示了靶向肝细胞生长因子受体（c-Met）的药物治疗过表达c-Met的晚期非小细胞肺癌的有希望的结果。我们评估了在现实世界中诊断NSCLC的c-Met免疫组织化学（IHC）的反射测试。
方法：我们回顾性收集了临床，我们机构2021年1月至2023年6月诊断为NSCLC的病例的病理和分子数据。我们进行了c-MetIHC（SP44克隆），并使用H评分和三层分类对表达进行评分。
结果：391例c-MetIHC染色可解释。诊断时的中位年龄为70岁（范围25-89岁），包括234名男性（男女比例为1：5）。58%的样本来自手术切除，35%来自活检，8%来自细胞学程序。52％的病例被分类为c-Met阳性（H评分≥150），19％被分类为c-Methigh（≥50％，3+).43％的c-Metneg在诊断时出现淋巴结和/或内脏转移，而55％的c-Methigh（p=0.042）。23％的腺癌显示c-Methigh表达，而鳞状细胞癌为3％（p=0.004）。27％的c-Metneg病例的PD-L1表达较高，而58％的c-Methigh病例（p<0.001）。METex14跳跃存在于8%的c-Methigh病例中。
结论：非小细胞肺癌患者每日常规系统c-Met检测是可行的，强调与临床病理和分子特征的潜在相关性。
方法：我们回顾性收集了临床，我们机构2021年1月至2023年6月诊断为NSCLC的病例的病理和分子数据。我们进行了c-MetIHC（SP44克隆），并使用H评分和三层分类对表达进行评分。
结果：391例c-MetIHC染色可解释。诊断时的中位年龄为70岁（范围25-89岁），包括234名男性（男女比例为1：5）。58%的样本来自手术切除，35%来自活检，8%来自细胞学程序。52％的病例被分类为c-Met阳性（H评分≥150），19％被分类为c-Methigh（≥50％，3+).43％的c-Metneg在诊断时出现淋巴结和/或内脏转移，而55％的c-Methigh（p=0.042）。23％的腺癌显示c-Methigh表达，而鳞状细胞癌为3％（p=0.004）。27％的c-Metneg病例的PD-L1表达较高，而58％的c-Methigh病例（p<0.001）。METex14跳跃存在于8%的c-Methigh病例中。
结论：非小细胞肺癌患者每日常规系统c-Met检测是可行的，强调与临床病理和分子特征的潜在相关性。
